Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
novadigm.net

See what CB Insights has to offer

Stage

Series B | Alive

Total Raised

$35.16M

Last Raised

$14M | 8 yrs ago

About NovaDigm Therapeutics

NovaDigm Therapeutics is developing vaccines to protect patients from fungal and bacterial infections, which can be life-threatening and drug resistant. The company's lead product candidate, NDV-3, is a recombinant glycoprotein vaccine containing a candidal surface antigen, agglutinin-like sequence 3 protein or Als3. Results from a Phase 1 clinical trial demonstrated that a single dose of the NDV-3 vaccine was safe, well-tolerated and induced strong antibody and T-cell immune responses in healthy adults.

NovaDigm Therapeutics Headquarter Location

4201 James Ray Drive Suite 2200

Grand Forks, North Dakota, 58202,

United States

701-757-5161

Latest NovaDigm Therapeutics News

Candidiasis Market Size & Trends 2020 – expected to reach US$ 1,307.2 Million With CAGR of 4.6% by 2026, Owing Increasing Prevalence of Candidiasis

Mar 2, 2021

Search jobs 02-Mar-2021 Candidiasis Market Size & Trends 2020 – expected to reach US$ 1,307.2 Million With CAGR of 4.6% by 2026, Owing Increasing Prevalence of Candidiasis Impact Analysis of Covid-19 The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters. Global Candidiasis Market , by Drug Class (Azoles, Echinocandins, Polyenes, and Flucytosine), by Type (Candida Infections of the Mouth, Throat, and Esophagus, Vaginal Candidiasis, and Invasive/Systemic Candidiasis), By Route of Administration (Oral, Parenteral, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 873.8 million in 2017, and is projected to exhibit a CAGR of 4.6% over the forecast period (2018–2026), as highlighted in a new report published by Coherent Market Insights. Request for the trending sample of this report: https://www.coherentmarketinsights.com/insight/request-sample/229 Increasing prevalence of candidiasis is expected to fuel growth of the global candidiasis market over the forecast period. For instance, according to the study, ‘National Burden of Candidemia, United States, 2017, published in November 2018, in the journal Open Forum Infectious Diseases, invasive candidiasis (candidemia) is one of the most common bloodstream infections in the U.S. and the average incidence for the disease was around 9 per 100,000 people during 2013–2017. R&D of new vaccines for the treatment of candidiasis is expected to boost growth of the global candidiasis market over the forecast period. For instance, in August 2019, researchers from the Los Angeles Biomedical Research Institute (LA BioMed), a spinoff company of NovaDigm Therapeutics, started developing the vaccine-NDV-3A to prevent infections caused by C. auris in humans, after successfully immunizing and demonstrating its clinical efficacy in mice. Quick Buy – Candidiasis Market Research Report: https://www.coherentmarketinsights.com/insight/buy-now/229 Increasing number of clinical trials related to the treatment of fungal diseases is expected to propel growth of the global candidiasis market. For instance, in 2017, the University Hospital of Cologne initiated a clinical trial to evaluate drug candidate SCY-078 in patients with fungal diseases that are refractory to or intolerant of standard antifungal treatment, in Europe. Major players in the market are focused on adopting M&A strategies to expand their product portfolio. For instance, in March 2018, Viamet Pharmaceuticals (NC), Inc. acquired Viamet Pharmaceuticals. The acquisition included the company’s product candidate, VT-1161, which successfully completed Phase 2b clinical trials for the treatment of recurrent vulvovaginal candidiasis (RVVC) and onychomycosis, or fungal nail infection. Similarly, in 2014, NovaDigm Therapeutics acquired the rights to three Candida vaccine antigens from the Los Angeles BioMedical Research Institute at Harbor-UCLA Medical Center. Browse 40 Market Data Tables and 38 Figures spread through 178 Pages and in-depth TOC on “Candidiasis Market”- Global Forecast to 2026 by Drug Class (Azoles, Echinocandins, Polyenes, and Flucytosine), by Type (Candida Infections of the Mouth, Throat, and Esophagus, Vaginal Candidiasis, and Invasive/Systemic Candidiasis), By Route of Administration (Oral, Parenteral, and Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) To know the latest trends and insights prevalent in the global candidiasis market press release, click the link below: https://www.coherentmarketinsights.com/press-release/candidiasis-market-to-surpass-us-13072-million-by-2026-2454 Key Takeaways The global candidiasis market is expected to exhibit a CAGR of 4.6% over the forecast period Among drug class, the azoles segment held dominant position in the global candidiasis market in 2017. Azoles are considered as the first-line agents in the treatment of various types of candidiasis such as esophageal and vaginal candidiasis. Among type, the vaginal candidiasis segment held dominant position in the global candidiasis market in 2017, owing to R&D in this segment Among route of administration, the oral segment held dominant position in the global candidiasis market in 2017. Several antifungal drugs used for the treatment and management of candidiasis are available in oral dosage form. Major players operating in the global candidiasis market include Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., and Pfizer, Inc. Got any Query? Feel free to ask us at https://www.coherentmarketinsights.com/insight/talk-to-analyst/229 About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services. To know more about us, please visit our website –  www.coherentmarketinsights.com Contact:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing NovaDigm Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

NovaDigm Therapeutics is included in 3 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

R

Regenerative Medicine

1,708 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharmaceuticals

5,731 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

NovaDigm Therapeutics Patents

NovaDigm Therapeutics has filed 5 patents.

The 3 most popular patent topics include:

  • Animal fungal diseases
  • Antifungals
  • Bacterial diseases
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/7/2017

12/8/2020

Piperazines, Antifungals, Animal fungal diseases, Pregnanes, Fluoroarenes

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

3/7/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

12/8/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Piperazines, Antifungals, Animal fungal diseases, Pregnanes, Fluoroarenes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

NovaDigm Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

NovaDigm Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.